Immune Checkpoint Blockade for the Treatment of Hodgkin Lymphoma

Figures & data

Table 1 Active or Recently Completed Clinical Trials Using Checkpoint Inhibitors (CPIs) in Hodgkin Lymphoma

Title	Line	Phase	NCT	Status	Notes
Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma (INDIE)	Frontline	II	NCT04837859	Recruiting	Tislelizumab alone or in combination with AVD followed by RT if PET positive after therapy
Immunotherapy (Nivolumab or Brentuximab Vedotin) plus Combination Chemotherapy in Treating Patients with Newly Diagnosed Stage III–IV Classic Hodgkin Lymphoma	Frontline	III	NCT03907488	Recruiting	BV+AVD is used as standard of care cohort
Nivolumab and Brentuximab Vedotin in Treating Older Patients with Untreated Hodgkin Lymphoma	Frontline	II	NCT02758717	Active, not recruiting	Age >60 years or unsuitable for standard chemotherapy
Brentuximab Vedotin and Nivolumab in Treating Patients with Early-Stage Classic Hodgkin Lymphoma	Frontline	II	NCT03712202	Recruiting	Arms: Nivo+BV, Nivo+ABVD, Nivo+BV+AVD
Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients with Refractory or Relapsed HL (NICE Trial)	Second-line therapy	II	NCT03016871	Recruiting	Nivolumab given concurrently with chemotherapy
A Study of Brentuximab Vedotin Combined with Nivolumab for Relapsed or Refractory Hodgkin Lymphoma	Second-line therapy	I/II	NCT02572167	Recently completed	Previously treated with BV, immune-oncology agents, or SCT excluded
Immune Checkpoint Inhibitors and Radiotherapy in Relapsed/Refractory Hodgkin Lymphoma (ICI-RT-1)	At least 1 prior line	R	NCT04419441	Recruiting	No other therapies allowed outside of CPI and RT
Umbralisib and Pembrolizumab in Treating Patients with Relapsed or Refractory Classical Hodgkin Lymphoma	At least 1 prior line	II	NCT03776864	Recruiting	Prior CPI use allowed
Brentuximab Vedotin and Nivolumab with or Without Ipilimumab in Treating Patients with Relapsed or Refractory Hodgkin Lymphoma	At least 1 prior line	I/II	NCT01896999	Recruiting	12 arms during phase I. Two arms during phase II
Gemcitabine, Bendamustine, and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma	At least 1 prior line	I/II	NCT03739619	Active, not recruiting	Previously allogeneic SCT excluded
Pembrolizumab and Vorinostat in Treating Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, or Hodgkin Lymphoma	At least 1 prior line	I	NCT03150329	Recruiting	Not candidates for ASCT or declined ASCT
Nivolumab and Ipilimumab in Treating Patients with HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery	At least 1 prior line	I	NCT02408861	Recruiting	Includes cohort of HIV-associated classical Hodgkin lymphoma
RadVax for Relapsed/Refractory Hodgkin’s Lymphoma: A Phase II Trial of Nivolumab + Low Dose Radiotherapy for Incomplete Responders	At least 1 prior line	II	NCT03495713	Recruiting	Radiotherapy given if not in CR by week 8. Need >2 sites of measurable disease
Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated with Brentuximab Vedotin or Checkpoint Inhibitors	At least 1 prior line	II	NCT05039073	Not yet recruiting	Previously treated with brentuximab vedotin or CPIs
Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma	At least 2 prior lines	I	NCT03843294	Recruiting	Includes post-ASCT consolidation for high-risk patients. Prior allogeneic SCT and solid organ transplant excluded
A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients with Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 812)	Ineligible or relapse after ASCT	III	NCT03138499	Recently completed	Must have at least one lesion that is >15 mm in the longest diameter
Ipilimumab or Nivolumab in Treating Patients with Relapsed Hematologic Malignancies After Donor Stem Cell Transplant	Post allogeneic SCT relapse	I	NCT01822509	Recently completed	Must have baseline donor T-cell chimerism of ≥20%
Nivolumab and Brentuximab Vedotin After Stem Cell Transplant in Treating Patients with Relapsed or Refractory High-Risk Classical Hodgkin Lymphoma	Post ASCT	II	NCT03057795	Active, not recruiting	Complex high-risk disease definition in trial details
A Study of Anti-PD-1 AK105 in Patients with Relapsed or Refractory Classic Hodgkin Lymphoma	Post ASCT or at least 2 lines of prior therapy	I/II	NCT03722147	Unknown	AK105 is an anti-PD-1 antibody

Abbreviations: AVD, adriamycin, vinblastine, dacarbazine; ABVD, adriamycin, bleomycin, vinblastine, dacarbazine; ASCT, autologous stem cell transplant; SCT, stem cell transplant; BV, brentuximab vedotin; R, retrospective; CR, complete response; Nivo, nivolumab; PD, programmed cell death; CPI, checkpoint inhibitor; PET, positron emission tomography; mm, millimeter; RT, radiation therapy; HIV, human immunodeficiency virus.